Order reprints

Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review

Guoxin Hou Binbin Song

*Corresponding author: Binbin Song ab_wy2005@163.com

MBE2019,5,5923doi:10.3934/mbe.2019296

Gastric cancer is one of the most common gastrointestinal tumors. Most patients have been in advanced stage at diagnosis and lack effective treatment. Molecular targeted drugs have become new therapeutic strategies. MET is an important driving gene for the development of gastric cancer. MET gene amplification and protein over-expression are closely related to the invasion and metastasis, late stage and poor prognosis of gastric cancer. Crizotinib is a small molecule inhibitor against MET. There are few reports of crizotinib in gastric cancer patients with c-MET amplification. This article reports a case of c-MET gene amplification in advanced gastric cancer with liver metastases. After 2 months of treatment with crizotinib, liver lesions were completely relieved and progression-free survival lasted for up to 20 months.

Please supply your name and a valid email address you yourself

Fields marked*are required

Article URL   http://www.aimspress.com/MBE/article/3887.html
Article ID   mbe-16-05-296
Editorial Email  
Your Name *
Your Email *
Quantity *

Copyright © AIMS Press All Rights Reserved